Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.

Inclusion Criteria:

• Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
• Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.
• Patient with life expectancy greater than 3 months
• Patient of legal age
• Patient affiliated to a social security scheme
• Signature of informed consent prior to any specific study procedure

Exclusion Criteria:

• Persons deprived of their liberty or under guardianship (including curatorship)
• Pregnant or breast-feeding patient